Willow Biosciences Inc Stock Price, News & Analysis

On March 22, 2023, Willow Biosciences (CANSF) and Suanfarma announced the successful completion of pilot-scale development and manufacturing for Cannabigerol (CBG) at Suanfarma's CIPAN manufacturing site. The project aims to fulfill the production batches required for qualification and registration by the end of 2023.

Willow's CBG is positioned for health, wellness, and consumer care applications, demonstrating safety and efficacy as an antioxidant and anti-inflammatory agent. The partnership aims to offer an end-to-end synthetic biology solution and enhance their product portfolio for pharmaceuticals and natural ingredients.

Willow Biosciences Inc. has appointed Dr. Jim Lalonde as an independent member of its Board of Directors, effective February 21, 2023. Dr. Lalonde is recognized for his contributions to enzyme engineering and biocatalysis, which have significantly advanced chemical production and drug development. With a history of strengthening R&D teams and driving business growth, his expertise is expected to support Willow's focus on expanding its R&D capabilities and diversifying its portfolio. Dr. Lalonde aims to leverage Willow's precision fermentation technology to foster innovation in health, wellness, food, and personal care markets.

Willow Biosciences Inc. (OTCQB: CANSF) has announced a follow-on engagement with Sandhill One, LLC to optimize a proprietary enzyme for the production of ursodeoxycholic acid (UDCA), an active pharmaceutical ingredient. This collaboration marks progress towards the company’s growth goals for 2023, aiming for increased revenue. The partnership with a major healthcare company focuses on a process that eliminates reliance on animal-sourced materials, promising cost-effective production. Willow anticipates several hundred thousand USD in research fees and future milestone payments as it moves towards commercialization of the enzyme by the end of the year.

Willow Biosciences Inc. (CANSF) has reviewed its key milestones achieved in 2022 and its business outlook for 2023. Major accomplishments include optimizing a new cannabigerol (CBG) process for commercial production, collaborations with Kalsec Inc., and the development of Astaxanthin, with a market potential exceeding $1 billion by 2027. For 2023, the company aims for substantial revenue growth, new partnerships, and efficient production. Willow has terminated a Joint Development Agreement for CBD to gain full control over its future in this market, emphasizing strategic optimization and a sustainable approach.

Willow Biosciences (CANSF) has announced strategic initiatives to enhance near-term revenue generation and minimize cash burn. Key actions include a shift towards revenue-generating pharmaceutical partnerships, consolidating R&D into a single lab in Mountain View, California, and outsourcing quality control testing. The company's workforce has been reduced to 31, with 77% in R&D, ensuring operational efficiency. As of September 30, 2022, Willow reported a strong cash position of $18.4 million with no debt, enabling a fully funded budget for 2023.

Willow Biosciences Inc. (TSX: WLLW, OTCQB: CANSF), a biotechnology leader, will host a webcast investor presentation on November 10, 2022, at 2:00 PM EST. The event will feature Willow's President and CEO, Dr. Peter Seufer-Wasserthal, and VP of Corporate Development, Troy Talkkari, discussing the company’s strategic areas. Investors can engage through a Q&A session. Pre-registration is required to access the live presentation. An archived version will be available on the company's website after the event.

Willow Biosciences Inc. (OTCQB: CANSF) announced its financial results for Q3 2022, reflecting strong liquidity with $18.7 million in working capital and $18.4 million in cash. The company appointed Dr. Peter Seufer-Wasserthal as President and CEO effective November 3, 2022, who had been interim CEO since July 2022. Willow is advancing its FutureGrown™ technology platform and has completed proof of concept for Astaxanthin. The company remains optimistic despite challenges in the cannabinoid market and is focusing on partnerships in the food and personal care sectors.

Willow Biosciences has successfully completed proof of concept and initiated yeast strain optimization for commercial production of astaxanthin, a potent antioxidant used in various industries. This development aims to meet the growing demand for natural, sustainably produced astaxanthin, currently valued at approximately $US 750 million with an expected growth rate of 8% annually. The company leverages its FutureGrown™ technology platform to produce cost-effective, high-purity astaxanthin. Willow plans to update stakeholders on key milestones and potential partnerships.

Willow Biosciences Inc. (OTCQB: CANSF) announced updates on its cannabigerol (CBG) product, focusing on operational advancements and regulatory progress. The Company is expanding its manufacturing network and expects to produce the first commercial CBG batches in H1 2023. Willow has successfully completed Stage 1 of the Generally Recognized as Safe (GRAS) assessment for its FutureGrown™ CBG and aims to initiate Stage 2 by Q3 2022. The Company has filed 12 patent applications related to cannabinoid production, positioning itself for sustained growth in the biosynthetic market.